Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014 (2014), Article ID 940591, 5 pages
http://dx.doi.org/10.1155/2014/940591
Case Report

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer

1D.M.R.T, GVN Hospital, Trichy 620008, India
2GVN Institute of Oncology, 2nd Cross, Thillai Nagar, Trichy 620015, India
3D.M, Manipal Hospital, Bangalore 560017, India
4S.L Raheja Hospital, Mumbai 400016, India

Received 14 December 2013; Accepted 11 February 2014; Published 3 April 2014

Academic Editors: T.-W. Chang and M. Ryberg

Copyright © 2014 K. N Srinivasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Ovarian cancer is the ninth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Albumin-bound paclitaxel is known to increase intratumoral concentration of the paclitaxel by a receptor-mediated transport process across the endothelial cell wall, thereby breaching the blood/tumor interface. We present below three cases in which nab-paclitaxel based chemotherapy has been used in different settings for patients with ovarian cancer. Case Presentation. In the first case nab-paclitaxel was used along with carboplatin in adjuvant setting, in the second case, nab-paclitaxel was used along with carboplatin and bevacizumab as second line chemotherapy in a relapsed ovarian cancer case, and the third case delineates the use of nab-paclitaxel along with cisplatin as third line chemotherapy. Conclusion. In all the three scenarios, patients tolerated the chemotherapy well, as well as responding well to nab-paclitaxel based chemotherapy. The patients are currently on long-term follow-up and have been having an uneventful postchemotherapy.